US11786472B2 - Preparation containing saxagliptin and method for producing the same - Google Patents
Preparation containing saxagliptin and method for producing the same Download PDFInfo
- Publication number
- US11786472B2 US11786472B2 US17/354,167 US202117354167A US11786472B2 US 11786472 B2 US11786472 B2 US 11786472B2 US 202117354167 A US202117354167 A US 202117354167A US 11786472 B2 US11786472 B2 US 11786472B2
- Authority
- US
- United States
- Prior art keywords
- weight
- plain tablet
- tablet part
- saxagliptin
- additive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- the present invention relates to a preparation containing saxagliptin and a method for producing the same.
- Saxagliptin ((1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1 3.7 ]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile monohydrate) is a selective inhibitor of dipeptidyl peptidase 4 (DPP4), which is a degradative enzyme of glucagon-like peptide-1 (GLP-1). GLP-1 stimulates pancreatic ⁇ -cells to enhance insulin secretion.
- DPP4 dipeptidyl peptidase 4
- GLP-1 glucagon-like peptide-1
- Saxagliptin is effective as a type 2 diabetes mellitus therapeutic agent because it promotes insulin secretion by inhibiting the degradation of GLP-1 and exerts a hypoglycemic effect.
- a type 2 diabetes mellitus therapeutic agent containing saxagliptin includes, for example, Onglyza (registered trademark) Tablet (Onglyza Tablet 2.5 mg Onglyza Tablet 5 mg Interview Form).
- Saxagliptin is known to be an unstable compound that tends to be intramolecularly cyclized.
- the cyclization reaction of saxagliptin is known to be accelerated by the producing process of a tablet containing saxagliptin and by contact with commonly used excipients.
- Japanese Patent No. 4901727 discloses a saxagliptin containing tablet containing a tablet core including microcrystalline cellulose and lactose monohydrate as fillers, croscarmellose sodium as a disintegrant, and magnesium stearate as a lubricant, an inner seal coating layer including polyvinyl alcohol (PVA)-based polymer, and a second coating layer arranged on the inner seal coating layer and containing saxagliptin and the PVA-based polymer.
- Japanese Patent No. 5837072 discloses a saxagliptin containing tablet containing a water-soluble antioxidant such as ascorbic acid or propyl gallate in the inner seal coating layer and the second coating layer.
- One of the objects of the present invention is to provide a preparation containing saxaglipin having improved stability and a method for producing the same.
- a preparation containing saxagliptin including a plain tablet part containing one or more first additive agent selected from a group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate, the plain tablet part containing less than 35% by weight of crystalline cellulose with respect to 100% by weight of the plain tablet part, and a film coating part in contact with the plain tablet part and containing saxagliptin, a salt thereof, or a hydrate thereof, and a method for producing the same is provided.
- a first additive agent selected from a group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate
- the plain tablet part may further contain one or more second additive agent selected from a group consisting of partially pregelatinized starch, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, carmellose, carmellose calcium, and corn starch.
- one or more second additive agent selected from a group consisting of partially pregelatinized starch, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, carmellose, carmellose calcium, and corn starch.
- the second additive agent may be selected from a group consisting of croscarmellose sodium, carmellose, and carmellose calcium.
- the plain tablet part may contain 59% by weight or more of the first additive agent with respect to 100% by weight of the plain tablet part.
- the plain tablet part may contain 2.5% by weight or more of the second additive agent with respect to 100% by weight of the plain tablet part.
- the plain tablet part may contain 40% by weight or less of the second additive agent with respect to 100% by weight of the plain tablet part.
- the first additive agent may be the D-mannitol or lactose
- the second additive agent may be the croscarmellose sodium
- the plain tablet part may contain 69% by weight or more of the first additive agent and the second additive agent with respect to 100% by weight of the plain tablet part.
- the film coating part may contain 40% by weight or more of polyvinyl alcohol with respect to 100% by weight of the film coating part excluding the saxagliptin.
- FIG. 1 A is a cross-sectional view of a preparation containing saxagliptin according to the present embodiment
- FIG. 1 B is a cross-sectional view of a preparation containing saxagliptin according to the present embodiment
- FIG. 2 is a table showing the type and amount of the additive agent and the amount of iminopiperazine ring (%) contained in the Examples and Comparative Examples;
- FIG. 3 is a table showing the type and amount of the additive agent and the amount of iminopiperazine ring (%) contained in the Examples and Comparative Examples;
- FIG. 4 is a table showing the type and amount of the additive agent and the amount of iminopiperazine ring (%) contained in the Examples and Comparative Examples;
- FIG. 5 is a table showing the type and amount of the additive agent and the amount of iminopiperazine ring (%) contained in the Examples and Comparative Examples.
- Saxagliptin of the present embodiment is preferably (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1 3.7 ]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile monohydrate.
- the present invention is not limited thereto, saxagliptin, a salt thereof, or a hydrate thereof may be used.
- the content of saxagliptin can be appropriately selected according to the expected therapeutic effect, and, for example, one tablet of a preparation containing saxagliptin includes 2.5 mg or more and 5 mg or less of saxagliptin.
- a preparation 1 containing saxagliptin according to an embodiment of the present invention is a coated tablet containing a plain tablet part 10 and a film coating part 20 containing saxagliptin.
- the film coating part 20 is arranged so as to cover the surface of the plain tablet part 10 .
- a protective part 30 may be further included as shown in FIG. 1 B .
- the protective part 30 is arranged so as to cover the surface of the film coating part 20 .
- the plain tablet part contains, for example, one or more additive agents selected from the group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate.
- the plain tablet part in the present embodiment preferably contains 59% by weight or more, preferably 65% by weight or more, and more preferably 84% by weight or more of one or more additive agents selected from the group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate with respect to 100% by weight of the plain tablet part.
- the plain tablet part in the present embodiment contains 59% by weight or more of one or more additive agents selected from the group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate with respect to 100% by weight of the plain tablet part, the generation of a related substance of saxagliptin upon storage can be suppressed and the stability of saxagliptin can be improved.
- the plain tablet part according to an embodiment preferably does not contain crystalline cellulose.
- the content of crystalline cellulose in the plain tablet part in the present embodiment is preferably less than 35% by weight, more preferably 10% by weight or less with respect to 100% by weight of the plain tablet part.
- the plain tablet part according to an embodiment may further contain croscarmellose sodium, partially pregelatinized starch, low-substituted hydroxypropyl cellulose, crospovidone, carmellose, carmellose calcium, or corn starch, and the like.
- An additive agent having a carboxymethyl cellulose structure such as croscarmellose sodium, carmellose, or carmellose calcium is particularly preferred because of its excellent stabilization of saxagliptin. It is more preferable that the plain tablet part in the present embodiment contains 2.5% by weight or more and 40% by weight or less of croscarmellose sodium, carmellose, or carmellose calcium with respect to 100% by weight of the plain tablet part.
- the plain tablet part in the present embodiment contains 2.5% by weight or more and 15% by weight or less of croscarmellose sodium, carmellose, or carmellose calcium with respect to 100% by weight of the plain tablet part. Since the plain tablet part in the present embodiment contains croscarmellose sodium, carmellose, or carmellose calcium, the generation of a related substance of saxagliptin upon storage can be suppressed and the stability of saxagliptin can be improved.
- the plain tablet part according to an embodiment preferably contains 69% by weight or more, and more preferably 90% by weight or more of D-mannitol and croscarmellose sodium, or lactose and croscarmellose sodium with respect to 100% by weight of the plain tablet part. Since the plain tablet part in the present embodiment contains 69% by weight or more of D-mannitol and croscarmellose sodium, or lactose and croscarmellose sodium with respect to 100% by weight of the plain tablet part, the generation of a related substance of saxagliptin upon storage can be suppressed and the stability of saxagliptin can be improved.
- the plain tablet part according to an embodiment may further contain magnesium stearate or the like.
- the plain tablet part in the present embodiment preferably contains 0.5% by weight or more and 1% by weight or less of magnesium stearate with respect to 100% by weight of the plain tablet part.
- the plain tablet part according to an embodiment is coated by the film coating part containing saxagliptin.
- the plain tablet part and the film coating part are in direct contact with each other.
- the film coating part according to an embodiment contains saxagliptin.
- the film coating part according to an embodiment is preferably a polyvinyl alcohol-based film.
- the film coating part according to an embodiment preferably contains one or more additive agents selected from the group consisting of, for example, polyvinyl alcohol, polyethylene glycol, talc, and titanium oxide.
- the film coating part in the present embodiment may contain, for example, 40% by weight of polyvinyl alcohol, 20% by weight of polyethylene glycol, 15% by weight of talc, and 25% by weight of titanium oxide with respect to 100% by weight of the film coating part excluding saxagliptin.
- the film coating part containing saxagliptin according to an embodiment may be further coated by the protective part.
- the film coating part and the protective part may be in direct contact with each other.
- the protective part according to an embodiment may have the same composition as the film coating part other than containing no saxagliptin.
- the protective part may be a polyvinyl alcohol-based film.
- the protective part may contain one or more additive agents selected from the group consisting of, for example, polyvinyl alcohol, polyethylene glycol, talc, and titanium oxide.
- the protective part in the present embodiment may contain, for example, 40% by weight of polyvinyl alcohol, 20% by weight of polyethylene glycol, 15% by weight of talc, and 25% by weight of titanium oxide with respect to 100% by weight of the protective part.
- the preparation containing saxagliptin by incorporating a specific additive agent into the plain tablet part, the generation of a related substance of saxagliptin upon storage can be suppressed and the stability of saxagliptin can be improved even if the plain tablet part is directly coated with the film containing saxagliptin.
- the preparation containing saxagliptin according to the present embodiment can be produced according to a producing method known in the pharmaceutical field.
- the additive agents selected from the above are homogeneously mixed, and the resulting mixture is tableted to produce the plain tablet part.
- other additive agents may be further added.
- the plain tablet part can be produced by compression molding with a commonly used tableting machine. For molding, any shape can be applied, for example, tablet, oval, spherical, or rod-shaped.
- the resulting tablet part is then coated with the film containing saxagliptin to produce a preparation containing saxagliptin.
- Saxagliptin and the additive agent selected from the above are dissolved or dispersed in the solvent to prepare a coating liquid.
- other additive agents may be further added.
- the film coating part can be produced by directly spraying the resulting coating liquid onto the plain tablet part with a known coating apparatus to coat the plain tablet part and removing the solvent.
- the resulting coated tablets may then be further coated with a saxagliptin-free film.
- the additive agents selected from the above are dissolved or dispersed in the solvent to prepare a coating liquid. At this time, other additive agents may be further added.
- the protective part can be produced by directly spraying the resulting coating liquid onto the film coating part with a known coating apparatus to coat the film coating part and removing the solvent.
- the generation of a related substance of saxagliptin upon storage can be suppressed and the stability of saxagliptin can be improved even if the plain tablet part is directly coated with the film containing saxagliptin.
- the coating liquid was prepared by dissolving or dispersing 2.64 mg of saxagliptin hydrate, 8 mg of polyvinyl alcohol, 4 mg of polyethylene glycol, 3 mg of talc, and 5 mg of titanium oxide per one tablet of each plain tablet in 200 g of hydrochloric acid, and by adjusting the pH to about 2 by adding sodium hydroxide.
- the preparation containing saxagliptin was obtained by spraying the coating liquid onto the surface of the plain tablet part using HC-LABO (Freund Corporation) to coat the tablet part and removing the solvent.
- the preparation containing saxagliptin was stored under the condition of 25° C., 75% RH for one month.
- the purity of the preparation containing saxagliptin after storage was evaluated using a HPLC method.
- the sum of the peak areas of the components of saxagliptin and the related substance derived from saxagliptin obtained on a chromatogram was set to 100% by an area percentage method, and the amount of iminopiperazine ring (%), which was the main related substance derived from saxagliptin, was calculated from the ratio of the peak area.
- the type and amount (mg) of the additive agent and the amount of iminopiperazine ring (%) contained in each Example, Comparative Example are shown in FIGS. 2 to 5 .
- FIG. 2 shows the amount of iminopiperazine ring (%) derived from saxagliptin after storage in Examples 1 to 4 and Comparative Example 1.
- Examples 1 to 4 containing 99% by weight of D-mannitol, lactose, anhydrous lactose, or anhydrous dibasic calcium phosphate with respect to 100% by weight of the plain tablet part showed a low amount of iminopiperazine ring (%).
- Comparative Example 1 containing 99% by weight of crystalline cellulose with respect to 100% by weight of the plain tablet part showed a high amount of iminopiperazine ring (%).
- FIG. 3 shows the amount of iminopiperazine ring (%) derived from saxagliptin after storage in Examples 5 to 10 and Comparative Example 2.
- Examples 5 to 10 containing 99% by weight of D-mannitol and low-substituted hydroxypropyl cellulose, D-mannitol and partially pregelatinized starch, D-mannitol and crospovidone, D-mannitol and carmellose, D-mannitol and carmellose calcium, or D-mannitol and corn starch with respect to 100% by weight of the plain tablet part showed a lower amount of iminopiperazine ring (%) compared to Example 1.
- Comparative Example 2 containing 99% by weight of D-mannitol and sodium starch glycolate with respect to 100% by weight of the plain tablet part showed a high amount of iminopiperazine ring (%).
- FIG. 4 shows the amount of iminopiperazine ring (%) derived from saxagliptin after storage in Examples 11 to 24 and Comparative Example 3.
- Examples 11 to 24 containing 59% by weight or more of D-mannitol with respect to 100% by weight of the plain tablet part showed a lower amount of iminopiperazine ring (%) compared to Example 1.
- Examples 11 to 19 containing 99% by weight of D-mannitol and croscarmellose sodium with respect to 100% by weight of the plain tablet part showed an even lower amount of iminopiperazine ring (%).
- Example 11 to 19 containing 2.5% by weight to 40% by weight of croscarmellose sodium with respect to 100% by weight of the plain tablet part showed an even lower amount of iminopiperazine ring (%).
- Examples 20 to 24 containing 10% by weight to 30% by weight of crystalline cellulose and 5% by weight of croscarmellose sodium with respect to 100% by weight of the plain tablet part showed a low amount of iminopiperazine ring (%).
- Comparative Example 3 containing 40% by weight of crystalline cellulose and 40% by weight of partially pregelatinized starch in the plain tablet part with respect to 100% by weight of the plain tablet part showed a high amount of iminopiperazine ring (%).
- FIG. 5 shows the amount of iminopiperazine ring (%) derived from saxagliptin after storage in Example 25 and Comparative Examples 4 to 15.
- Example 25 containing 99% by weight of lactose and croscarmellose sodium with respect to 100% by weight of the plain tablet part showed a lower amount of iminopiperazine ring (%) compared to Example 2.
- Comparative Examples 4 to 15 containing 35% by weight or more of crystalline cellulose in the plain tablet part with respect to 100% by weight of the plain tablet part showed a higher amount of iminopiperazine ring (%) than in Example 2.
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/371,932 US20240009134A1 (en) | 2020-06-23 | 2023-09-22 | Preparation containing saxagliptin and method for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020107612A JP2022003016A (en) | 2020-06-23 | 2020-06-23 | Saxagliptin-containing preparation and its manufacturing method |
JP2020-107612 | 2020-06-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/371,932 Continuation US20240009134A1 (en) | 2020-06-23 | 2023-09-22 | Preparation containing saxagliptin and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210393532A1 US20210393532A1 (en) | 2021-12-23 |
US11786472B2 true US11786472B2 (en) | 2023-10-17 |
Family
ID=79022726
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/354,167 Active US11786472B2 (en) | 2020-06-23 | 2021-06-22 | Preparation containing saxagliptin and method for producing the same |
US18/371,932 Pending US20240009134A1 (en) | 2020-06-23 | 2023-09-22 | Preparation containing saxagliptin and method for producing the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/371,932 Pending US20240009134A1 (en) | 2020-06-23 | 2023-09-22 | Preparation containing saxagliptin and method for producing the same |
Country Status (2)
Country | Link |
---|---|
US (2) | US11786472B2 (en) |
JP (1) | JP2022003016A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050266080A1 (en) | 2004-05-28 | 2005-12-01 | Desai Divyakant S | Coated tablet formulation and method |
US20130224296A1 (en) | 2010-09-03 | 2013-08-29 | Bristol-Myers Squibb Company | Drug Formulations Using Water Soluble Antioxidants |
US20140072628A1 (en) * | 2012-09-12 | 2014-03-13 | Glenmark Generics Ltd. | Stable pharmaceutical composition of saxagliptin |
US20150250734A1 (en) * | 2012-12-21 | 2015-09-10 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
-
2020
- 2020-06-23 JP JP2020107612A patent/JP2022003016A/en active Pending
-
2021
- 2021-06-22 US US17/354,167 patent/US11786472B2/en active Active
-
2023
- 2023-09-22 US US18/371,932 patent/US20240009134A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050266080A1 (en) | 2004-05-28 | 2005-12-01 | Desai Divyakant S | Coated tablet formulation and method |
JP4901727B2 (en) | 2004-05-28 | 2012-03-21 | ブリストル−マイヤーズ スクイブ カンパニー | Coated tablet formulation and method |
US20130224296A1 (en) | 2010-09-03 | 2013-08-29 | Bristol-Myers Squibb Company | Drug Formulations Using Water Soluble Antioxidants |
JP5837072B2 (en) | 2010-09-03 | 2015-12-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Formulations that use water-soluble antioxidants |
US20140072628A1 (en) * | 2012-09-12 | 2014-03-13 | Glenmark Generics Ltd. | Stable pharmaceutical composition of saxagliptin |
US20150250734A1 (en) * | 2012-12-21 | 2015-09-10 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
Non-Patent Citations (1)
Title |
---|
"Pharmaceutical Interview Form: Onglyza® tablets 2.5mg, 5mg." Revised on Aug. 2018 (9th edition), Kyowa Kirin Co., Ltd., Pharmaceutical, along with a partial English translation, cited in the Specification. |
Also Published As
Publication number | Publication date |
---|---|
JP2022003016A (en) | 2022-01-11 |
US20240009134A1 (en) | 2024-01-11 |
US20210393532A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2283826B1 (en) | Galenic formulations of organic compounds | |
EP0858328B1 (en) | Stable compositions containing n-propargyl-1-aminoindan | |
US20100247642A1 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
CN107205969B (en) | Pharmaceutical composition for treating diabetes | |
KR102357423B1 (en) | Pharmaceutical composition containing clomipramine and its manufacturing method | |
EP2550957A1 (en) | Effervescent formulations of vildagliptin | |
US6979462B1 (en) | Stabilization of solid drug formulations | |
WO2018211479A1 (en) | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof | |
JP2019526591A (en) | Pharmaceutical composition comprising rosuvastatin and ezetimibe and method for preparing the same | |
EP2034968B1 (en) | Galenical formulations of aliskiren and hydrochlorothiazide | |
US11786472B2 (en) | Preparation containing saxagliptin and method for producing the same | |
TW201323017A (en) | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin | |
EP4025194A1 (en) | A combination comprising vildagliptin and metformin | |
EP2753328A1 (en) | Dpp-iv inhibitor formulations | |
EP2101742B1 (en) | Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form | |
US20130189358A1 (en) | Saxagliptin pharmaceutical formulations | |
KR102496243B1 (en) | A tablet comprising atorvastatin and ezetimibe | |
EP1322294B1 (en) | Stabilization of solid thyroid drug formulations | |
KR20190045739A (en) | Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof | |
JP2016216425A (en) | Carvedilol-containing tablet | |
JP2001342185A (en) | Film-coated ranitidine hydrochloride tablet | |
RU2479310C2 (en) | Pharmaceutical composition for treating arterial hypertension and congestive cardiac failure and method for preparing it | |
US20230058432A1 (en) | Pharmaceutical composite formulation comprising proton pump inhibitor and antacid | |
US20060051410A1 (en) | Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid | |
TR2021016644A2 (en) | A FILM-COATED TABLET CONTAINING SAXAGLIPTIN AND AT LEAST ONE ANTIOXIDANT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SAWAI PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOZAWA, KENJI;IZUI, WATARU;NATSUME, AYANE;AND OTHERS;REEL/FRAME:056621/0202 Effective date: 20210617 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |